Bi-Specific Antibodies Therapy Industry Research Report 2023

Bi-Specific Antibodies Therapy Industry Research Report 2023


A bispecific antibody (BsAb), or specific monoclonal antibody (BsMAb) is an artificial protein comprised of fragments from two different antibodies. By virtue of the inclusion of two different antigen binding regions, a bispecific antibody is capable of recognizing and binding to two different antigens, or two different epitope on an antigen.

Highlights

The global Bi-Specific Antibodies Therapy market is projected to reach US$ million by 2029 from an estimated US$ million in 2023, at a CAGR of % during 2024 and 2029.

Global Bi-Specific Antibodies Therapy key players include Roche, Amgen, Sanofi, Pfizer, Johnson & Johnson, etc. Global top five manufacturers hold a share over 95%.

North America is the largest market, with a share about 65%, followed by Europe and China, both have a share over 30 percent. In terms of product, IgG-Based Antibodies is the largest segment, with a share over 85%. And in terms of application, the largest application is Haemophilia, followed by Cancer, etc.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Bi-Specific Antibodies Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bi-Specific Antibodies Therapy.

The Bi-Specific Antibodies Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Bi-Specific Antibodies Therapy market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Bi-Specific Antibodies Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Roche
Amgen
Sanofi
Pfizer
Johnson & Johnson
AstraZeneca
AbbVie
Lindis Biotech
MacroGenics, Inc
Genmab
Alphamab Co. Ltd
Akeso, Inc.

Product Type Insights

Global markets are presented by Bi-Specific Antibodies Therapy type, along with growth forecasts through 2029. Estimates on revenue are based on the price in the supply chain at which the Bi-Specific Antibodies Therapy are procured by the companies.

This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).

Bi-Specific Antibodies Therapy segment by Type
Fragment-Based Antibodies
IgG-Based Antibodies

Application Insights

This report has provided the market size (revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).

This report also outlines the market trends of each segment and consumer behaviors impacting the Bi-Specific Antibodies Therapy market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Bi-Specific Antibodies Therapy market.

Bi-Specific Antibodies Therapy Segment by Application
Cancer
Haemophilia
Other Non-Cancer Diseases

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2018-2029.

The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2022 because of the base year, with estimates for 2023 and forecast revenue for 2029.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Bi-Specific Antibodies Therapy market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bi-Specific Antibodies Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

This report will help stakeholders to understand the global industry status and trends of Bi-Specific Antibodies Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

This report stays updated with novel technology integration, features, and the latest developments in the market

This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Bi-Specific Antibodies Therapy industry.

This report helps stakeholders to gain insights into which regions to target globally

This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bi-Specific Antibodies Therapy.

This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Bi-Specific Antibodies Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Frequently Asked Questions

What factors will challenge the Product Name market growth?
Which end-use segment will expand at the fastest CAGR in the Product Name market?
Which are the emerging players in the Product Name market?
How concentrated is the Product Name market?
Which factors are positively contributing to the Product Name market growth?
Which are the novel product innovations in the Product Name market?
Which product segment will emerge as the most lucrative in the Product Name market?
Which factors are increasing the competition in the Product Name market?
Which are the strategic measures taken by the Product Name industry players?
Which region will witness inactive growth during the forecast period?
What key trends are likely to emerge in the Product Name market in the coming years?


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Bi-Specific Antibodies Therapy by Type
2.2.1 Market Value Comparison by Type (2018 VS 2022 VS 2029)
1.2.2 Fragment-Based Antibodies
1.2.3 IgG-Based Antibodies
2.3 Bi-Specific Antibodies Therapy by Application
2.3.1 Market Value Comparison by Application (2018 VS 2022 VS 2029)
2.3.2 Cancer
2.3.3 Haemophilia
2.3.4 Other Non-Cancer Diseases
2.4 Assumptions and Limitations
3 Bi-Specific Antibodies Therapy Breakdown Data by Type
3.1 Global Bi-Specific Antibodies Therapy Historic Market Size by Type (2018-2023)
3.2 Global Bi-Specific Antibodies Therapy Forecasted Market Size by Type (2023-2028)
4 Bi-Specific Antibodies Therapy Breakdown Data by Application
4.1 Global Bi-Specific Antibodies Therapy Historic Market Size by Application (2018-2023)
4.2 Global Bi-Specific Antibodies Therapy Forecasted Market Size by Application (2018-2023)
5 Global Growth Trends
5.1 Global Bi-Specific Antibodies Therapy Market Perspective (2018-2029)
5.2 Global Bi-Specific Antibodies Therapy Growth Trends by Region
5.2.1 Global Bi-Specific Antibodies Therapy Market Size by Region: 2018 VS 2022 VS 2029
5.2.2 Bi-Specific Antibodies Therapy Historic Market Size by Region (2018-2023)
5.2.3 Bi-Specific Antibodies Therapy Forecasted Market Size by Region (2024-2029)
5.3 Bi-Specific Antibodies Therapy Market Dynamics
5.3.1 Bi-Specific Antibodies Therapy Industry Trends
5.3.2 Bi-Specific Antibodies Therapy Market Drivers
5.3.3 Bi-Specific Antibodies Therapy Market Challenges
5.3.4 Bi-Specific Antibodies Therapy Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Bi-Specific Antibodies Therapy Players by Revenue
6.1.1 Global Top Bi-Specific Antibodies Therapy Players by Revenue (2018-2023)
6.1.2 Global Bi-Specific Antibodies Therapy Revenue Market Share by Players (2018-2023)
6.2 Global Bi-Specific Antibodies Therapy Industry Players Ranking, 2021 VS 2022 VS 2023
6.3 Global Key Players of Bi-Specific Antibodies Therapy Head office and Area Served
6.4 Global Bi-Specific Antibodies Therapy Players, Product Type & Application
6.5 Global Bi-Specific Antibodies Therapy Players, Date of Enter into This Industry
6.6 Global Bi-Specific Antibodies Therapy Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Bi-Specific Antibodies Therapy Market Size (2018-2029)
7.2 North America Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 North America Bi-Specific Antibodies Therapy Market Size by Country (2018-2023)
7.4 North America Bi-Specific Antibodies Therapy Market Size by Country (2024-2029)
7.5 United States
7.6 Canada
8 Europe
8.1 Europe Bi-Specific Antibodies Therapy Market Size (2018-2029)
8.2 Europe Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
8.3 Europe Bi-Specific Antibodies Therapy Market Size by Country (2018-2023)
8.4 Europe Bi-Specific Antibodies Therapy Market Size by Country (2024-2029)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Bi-Specific Antibodies Therapy Market Size (2018-2029)
9.2 Asia-Pacific Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Country (2018-2023)
9.4 Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Country (2024-2029)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
10 Latin America
10.1 Latin America Bi-Specific Antibodies Therapy Market Size (2018-2029)
10.2 Latin America Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Latin America Bi-Specific Antibodies Therapy Market Size by Country (2018-2023)
10.4 Latin America Bi-Specific Antibodies Therapy Market Size by Country (2024-2029)
9.4 Mexico
9.5 Brazil
11 Middle East & Africa
11.1 Middle East & Africa Bi-Specific Antibodies Therapy Market Size (2018-2029)
11.2 Middle East & Africa Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
11.3 Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Country (2018-2023)
11.4 Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Country (2024-2029)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
12 Players Profiled
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Bi-Specific Antibodies Therapy Introduction
11.1.4 Roche Revenue in Bi-Specific Antibodies Therapy Business (2017-2022)
11.1.5 Roche Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Bi-Specific Antibodies Therapy Introduction
11.2.4 Amgen Revenue in Bi-Specific Antibodies Therapy Business (2017-2022)
11.2.5 Amgen Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Detail
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Bi-Specific Antibodies Therapy Introduction
11.3.4 Sanofi Revenue in Bi-Specific Antibodies Therapy Business (2017-2022)
11.3.5 Sanofi Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Detail
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Bi-Specific Antibodies Therapy Introduction
11.4.4 Pfizer Revenue in Bi-Specific Antibodies Therapy Business (2017-2022)
11.4.5 Pfizer Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Detail
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Bi-Specific Antibodies Therapy Introduction
11.5.4 Johnson & Johnson Revenue in Bi-Specific Antibodies Therapy Business (2017-2022)
11.5.5 Johnson & Johnson Recent Development
11.6 AstraZeneca
11.6.1 AstraZeneca Company Detail
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Bi-Specific Antibodies Therapy Introduction
11.6.4 AstraZeneca Revenue in Bi-Specific Antibodies Therapy Business (2017-2022)
11.6.5 AstraZeneca Recent Development
11.7 AbbVie
11.7.1 AbbVie Company Detail
11.7.2 AbbVie Business Overview
11.7.3 AbbVie Bi-Specific Antibodies Therapy Introduction
11.7.4 AbbVie Revenue in Bi-Specific Antibodies Therapy Business (2017-2022)
11.7.5 AbbVie Recent Development
11.8 Lindis Biotech
11.8.1 Lindis Biotech Company Detail
11.8.2 Lindis Biotech Business Overview
11.8.3 Lindis Biotech Bi-Specific Antibodies Therapy Introduction
11.8.4 Lindis Biotech Revenue in Bi-Specific Antibodies Therapy Business (2017-2022)
11.8.5 Lindis Biotech Recent Development
11.9 MacroGenics, Inc
11.9.1 MacroGenics, Inc Company Detail
11.9.2 MacroGenics, Inc Business Overview
11.9.3 MacroGenics, Inc Bi-Specific Antibodies Therapy Introduction
11.9.4 MacroGenics, Inc Revenue in Bi-Specific Antibodies Therapy Business (2017-2022)
11.9.5 MacroGenics, Inc Recent Development
11.10 Genmab
11.10.1 Genmab Company Detail
11.10.2 Genmab Business Overview
11.10.3 Genmab Bi-Specific Antibodies Therapy Introduction
11.10.4 Genmab Revenue in Bi-Specific Antibodies Therapy Business (2017-2022)
11.10.5 Genmab Recent Development
11.11 Alphamab Co. Ltd
11.11.1 Alphamab Co. Ltd Company Detail
11.11.2 Alphamab Co. Ltd Business Overview
11.11.3 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Introduction
11.11.4 Alphamab Co. Ltd Revenue in Bi-Specific Antibodies Therapy Business (2017-2022)
11.11.5 Alphamab Co. Ltd Recent Development
11.12 Akeso, Inc.
11.12.1 Akeso, Inc. Company Detail
11.12.2 Akeso, Inc. Business Overview
11.12.3 Akeso, Inc. Bi-Specific Antibodies Therapy Introduction
11.12.4 Akeso, Inc. Revenue in Bi-Specific Antibodies Therapy Business (2017-2022)
11.12.5 Akeso, Inc. Recent Development
13 Report Conclusion
14 Disclaimer
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US$ Million)
Table 5. Global Bi-Specific Antibodies Therapy Market Size by Type (2018-2023) & (US$ Million)
Table 6. Global Bi-Specific Antibodies Therapy Revenue Market Share by Type (2018-2023)
Table 7. Global Bi-Specific Antibodies Therapy Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 8. Global Bi-Specific Antibodies Therapy Revenue Market Share by Type (2024-2029)
Table 9. Global Bi-Specific Antibodies Therapy Market Size by Application (2018-2023) & (US$ Million)
Table 10. Global Bi-Specific Antibodies Therapy Revenue Market Share by Application (2018-2023)
Table 11. Global Bi-Specific Antibodies Therapy Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 12. Global Bi-Specific Antibodies Therapy Revenue Market Share by Application (2024-2029)
Table 13. Global Bi-Specific Antibodies Therapy Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 14. Global Bi-Specific Antibodies Therapy Market Size by Region (2018-2023) & (US$ Million)
Table 15. Global Bi-Specific Antibodies Therapy Market Share by Region (2018-2023)
Table 16. Global Bi-Specific Antibodies Therapy Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 17. Global Bi-Specific Antibodies Therapy Market Share by Region (2024-2029)
Table 18. Bi-Specific Antibodies Therapy Market Trends
Table 19. Bi-Specific Antibodies Therapy Market Drivers
Table 20. Bi-Specific Antibodies Therapy Market Challenges
Table 21. Bi-Specific Antibodies Therapy Market Restraints
Table 22. Global Top Bi-Specific Antibodies Therapy Manufacturers by Revenue (US$ Million) & (2018-2023)
Table 23. Global Bi-Specific Antibodies Therapy Revenue Market Share by Manufacturers (2018-2023)
Table 24. Global Bi-Specific Antibodies Therapy Industry Manufacturers Ranking, 2021 VS 2022 VS 2023
Table 25. Global Key Players of Bi-Specific Antibodies Therapy, Headquarters and Area Served
Table 26. Global Bi-Specific Antibodies Therapy Manufacturers, Product Type & Application
Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Bi-Specific Antibodies Therapy by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. North America Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. North America Bi-Specific Antibodies Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 32. North America Bi-Specific Antibodies Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 33. Europe Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 34. Europe Bi-Specific Antibodies Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 35. Europe Bi-Specific Antibodies Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 36. Asia-Pacific Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 37. Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 38. Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 39. Latin America Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 40. Latin America Bi-Specific Antibodies Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 41. Latin America Bi-Specific Antibodies Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 42. Middle East & Africa Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 43. Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 44. Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 45. Roche Company Detail
Table 46. Roche Business Overview
Table 47. Roche Bi-Specific Antibodies Therapy Product
Table 48. Roche Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million)
Table 49. Roche Recent Development
Table 50. Amgen Company Detail
Table 51. Amgen Business Overview
Table 52. Amgen Bi-Specific Antibodies Therapy Product
Table 53. Amgen Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million)
Table 54. Amgen Recent Development
Table 55. Sanofi Company Detail
Table 56. Sanofi Business Overview
Table 57. Sanofi Bi-Specific Antibodies Therapy Product
Table 58. Sanofi Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million)
Table 59. Sanofi Recent Development
Table 60. Pfizer Company Detail
Table 61. Pfizer Business Overview
Table 62. Pfizer Bi-Specific Antibodies Therapy Product
Table 63. Pfizer Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million)
Table 64. Pfizer Recent Development
Table 65. Johnson & Johnson Company Detail
Table 66. Johnson & Johnson Business Overview
Table 67. Johnson & Johnson Bi-Specific Antibodies Therapy Product
Table 68. Johnson & Johnson Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million)
Table 69. Johnson & Johnson Recent Development
Table 70. AstraZeneca Company Detail
Table 71. AstraZeneca Business Overview
Table 72. AstraZeneca Bi-Specific Antibodies Therapy Product
Table 73. AstraZeneca Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million)
Table 74. AstraZeneca Recent Development
Table 75. AbbVie Company Detail
Table 76. AbbVie Business Overview
Table 77. AbbVie Bi-Specific Antibodies Therapy Product
Table 78. AbbVie Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million)
Table 79. AbbVie Recent Development
Table 80. Lindis Biotech Company Detail
Table 81. Lindis Biotech Business Overview
Table 82. Lindis Biotech Bi-Specific Antibodies Therapy Product
Table 83. Lindis Biotech Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million)
Table 84. Lindis Biotech Recent Development
Table 85. MacroGenics, Inc Company Detail
Table 86. MacroGenics, Inc Business Overview
Table 87. MacroGenics, Inc Bi-Specific Antibodies Therapy Product
Table 88. MacroGenics, Inc Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million)
Table 89. MacroGenics, Inc Recent Development
Table 90. Genmab Company Detail
Table 91. Genmab Business Overview
Table 92. Genmab Bi-Specific Antibodies Therapy Product
Table 93. Genmab Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million)
Table 94. Genmab Recent Development
Table 95. Alphamab Co. Ltd Company Detail
Table 96. Alphamab Co. Ltd Business Overview
Table 97. Alphamab Co. Ltd Bi-Specific Antibodies TherapyProduct
Table 98. Alphamab Co. Ltd Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million)
Table 99. Alphamab Co. Ltd Recent Development
Table 100. Akeso, Inc. Company Detail
Table 101. Akeso, Inc. Business Overview
Table 102. Akeso, Inc. Bi-Specific Antibodies TherapyProduct
Table 103. Akeso, Inc. Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million)
Table 104. Akeso, Inc. Recent Development
Table 105. Roche Company Information
Table 106. Roche Business Overview
Table 107. Roche Bi-Specific Antibodies Therapy Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US$ Million)
Table 108. Roche Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US$ Million) Portfolio
Table 109. Roche Recent Development
Table 110. Amgen Company Information
Table 111. Amgen Business Overview
Table 112. Amgen Bi-Specific Antibodies Therapy Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US$ Million)
Table 113. Amgen Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US$ Million) Portfolio
Table 114. Amgen Recent Development
Table 115. Sanofi Company Information
Table 116. Sanofi Business Overview
Table 117. Sanofi Bi-Specific Antibodies Therapy Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US$ Million)
Table 118. Sanofi Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US$ Million) Portfolio
Table 119. Sanofi Recent Development
Table 120. Pfizer Company Information
Table 121. Pfizer Business Overview
Table 122. Pfizer Bi-Specific Antibodies Therapy Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US$ Million)
Table 123. Pfizer Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US$ Million) Portfolio
Table 124. Pfizer Recent Development
Table 125. Johnson & Johnson Company Information
Table 126. Johnson & Johnson Business Overview
Table 127. Johnson & Johnson Bi-Specific Antibodies Therapy Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US$ Million)
Table 128. Johnson & Johnson Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US$ Million) Portfolio
Table 129. Johnson & Johnson Recent Development
Table 130. AstraZeneca Company Information
Table 131. AstraZeneca Business Overview
Table 132. AstraZeneca Bi-Specific Antibodies Therapy Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US$ Million)
Table 133. AstraZeneca Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US$ Million) Portfolio
Table 134. AstraZeneca Recent Development
Table 135. AbbVie Company Information
Table 136. AbbVie Business Overview
Table 137. AbbVie Bi-Specific Antibodies Therapy Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US$ Million)
Table 138. AbbVie Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US$ Million) Portfolio
Table 139. AbbVie Recent Development
Table 140. Lindis Biotech Company Information
Table 141. Lindis Biotech Business Overview
Table 142. Lindis Biotech Bi-Specific Antibodies Therapy Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US$ Million)
Table 143. Lindis Biotech Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US$ Million) Portfolio
Table 144. Lindis Biotech Recent Development
Table 145. MacroGenics, Inc Company Information
Table 146. MacroGenics, Inc Business Overview
Table 147. MacroGenics, Inc Bi-Specific Antibodies Therapy Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US$ Million)
Table 148. MacroGenics, Inc Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US$ Million) Portfolio
Table 149. MacroGenics, Inc Recent Development
Table 150. Genmab Company Information
Table 151. Genmab Business Overview
Table 152. Genmab Bi-Specific Antibodies Therapy Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US$ Million)
Table 153. Genmab Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US$ Million) Portfolio
Table 154. Genmab Recent Development
Table 155. Alphamab Co. Ltd Company Information
Table 156. Alphamab Co. Ltd Business Overview
Table 157. Alphamab Co. Ltd Bi-Specific Antibodies TherapyRevenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US$ Million)
Table 158. Alphamab Co. Ltd Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US$ Million) Portfolio
Table 159. Alphamab Co. Ltd Recent Development
Table 160. Akeso, Inc. Company Information
Table 161. Akeso, Inc. Business Overview
Table 162. Akeso, Inc. Bi-Specific Antibodies TherapyRevenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US$ Million)
Table 163. Akeso, Inc. Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US$ Million) Portfolio
Table 164. Akeso, Inc. Recent Development
Table 165. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Bi-Specific Antibodies Therapy Product Picture
Figure 5. Global Bi-Specific Antibodies Therapy Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 6. Global Bi-Specific Antibodies Therapy Market Share by Type: 2022 VS 2029
Figure 7. Fragment-Based Antibodies Product Picture
Figure 8. IgG-Based Antibodies Product Picture
Figure 9. Global Bi-Specific Antibodies Therapy Market Size by Application (2023-2029) & (US$ Million)
Figure 10. Global Bi-Specific Antibodies Therapy Market Share by Application: 2022 VS 2029
Figure 11. Cancer Product Picture
Figure 12. Haemophilia Product Picture
Figure 13. Other Non-Cancer Diseases Product Picture
Figure 14. Global Bi-Specific Antibodies Therapy Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Bi-Specific Antibodies Therapy Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Bi-Specific Antibodies Therapy Market Share by Region: 2022 VS 2029
Figure 17. Global Bi-Specific Antibodies Therapy Market Share by Players in 2022
Figure 18. Global Bi-Specific Antibodies Therapy Players, Date of Enter into This Industry
Figure 19. Global Top 5 and 10 Bi-Specific Antibodies Therapy Players Market Share by Revenue in 2022
Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 21. North America Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. North America Bi-Specific Antibodies Therapy Market Share by Country (2018-2029)
Figure 23. United States Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Canada Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Europe Bi-Specific Antibodies Therapy Market Share by Country (2018-2029)
Figure 27. Germany Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. France Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. U.K. Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Italy Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Russia Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Nordic Countries Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Asia-Pacific Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Asia-Pacific Bi-Specific Antibodies Therapy Market Share by Country (2018-2029)
Figure 35. China Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Japan Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. South Korea Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Southeast Asia Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. India Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Australia Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Latin America Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Latin America Bi-Specific Antibodies Therapy Market Share by Country (2018-2029)
Figure 43. Mexico Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Brazil Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Middle East & Africa Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Middle East & Africa Bi-Specific Antibodies Therapy Market Share by Country (2018-2029)
Figure 47. Turkey Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Saudi Arabia Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. UAE Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 50. Roche Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2018-2023)
Figure 51. Amgen Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2018-2023)
Figure 52. Sanofi Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2018-2023)
Figure 53. Pfizer Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2018-2023)
Figure 54. Johnson & Johnson Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2018-2023)
Figure 55. AstraZeneca Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2018-2023)
Figure 56. AbbVie Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2018-2023)
Figure 57. Lindis Biotech Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2018-2023)
Figure 58. MacroGenics, Inc Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2018-2023)
Figure 59. Genmab Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2018-2023)
Figure 60. Alphamab Co. Ltd Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2018-2023)
Figure 61. Akeso, Inc. Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2018-2023)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings